No Matter How You Splice It, RBM39 Inhibition Targets Spliceosome Mutant AML

Cancer Cell. 2019 Mar 18;35(3):337-339. doi: 10.1016/j.ccell.2019.02.013.

Abstract

A report in this issue of Cancer Cell identifies the RNA-binding protein RBM39 as a potential target in spliceosome mutant AML that can be targeted by existing sulfonamide drugs. These results support a proposed clinical trial in patients with myeloid malignancies bearing spliceosome mutations relapsed or refractory to standard therapy.

Publication types

  • Comment

MeSH terms

  • Humans
  • Leukemia, Myeloid, Acute*
  • Mutation
  • RNA-Binding Proteins / genetics
  • Spliceosomes*
  • Sulfonamides

Substances

  • RNA-Binding Proteins
  • Sulfonamides